We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Can Galafold Drive Amicus' Growth Through the Rest of 2025?
Read MoreHide Full Article
Key Takeaways
Amicus' Galafold recorded $233.1M in H1 2025 sales, up 11% year over year.
Label expansion and global approvals have boosted Galafold's revenue growth in recent times.
Teva settlement blocks Galafold generics in the United States until January 2037.
Amicus Therapeutics’ (FOLD - Free Report) lead product, Galafold (migalastat), has been driving the majority of the company’s revenues. The drug remains a key top-line driver for the company.
Galafold is the first oral precision medicine approved for treating patients with Fabry disease who have amenable genetic variants. The drug is approved in several countries across the world, including the United States, the European Union, the United Kingdom and Japan.
Amicus’ first marketed product, Galafold, has shown solid uptake since its launch. The sales of the drug have been rising consistently year over year. In the first six months of 2025, Galafold generated sales worth $233.1 million, which increased around 11% on a year-over-year basis. Our model estimates for Galafold sales suggest a CAGR of 11.7% over the next three years.
Label expansion, combined with approvals in additional geographies, has been driving Galafold sales in recent quarters, and the momentum is expected to continue in the remainder of 2025. The drug also has a strong IP portfolio in the United States, providing patent protection through 2038.
Last October, Amicus signed a licensing agreement with Teva Pharmaceuticals (TEVA - Free Report) , resolving the patent lawsuit that it had filed earlier. The litigation arose after Teva submitted an abbreviated new drug application seeking approval to sell a generic version of Amicus' Galafold 123 mg capsules before the related patents expired.
Per the settlement terms, TEVA will not be able to sell its generic version of Galafold in the United States until January 2037.
Besides Galafold, Amicus is also making good progress with Pombiliti (cipaglucosidase alfa) + Opfolda (miglustat), a two-component therapy, which is approved for treating adults with late-onset Pompe disease (LOPD). The approval of Pombiliti + Opfolda helped FOLD tap into a market with a significant commercial opportunity.
During the first six months of 2025, the combo drug generated sales worth $46.8 million, up around 74% on a year-over-year basis.
FOLD’s Dependence on Galafold & Competition in the Target Market
Currently, Amicus remains heavily dependent on Galafold for its overall revenue growth, making the company vulnerable to any regulatory setbacks for the drug. Though Pombiliti + Opfolda has been approved in Europe and the United States, it is yet to generate incremental sales. Any regulatory setback for the approved drugs will hinder the company’s growth prospects.
Also, competition looms large from established players in the target market. Several pharmaceutical and biotechnology companies currently market and sell products for treating lysosomal storage disorders, including Fabry disease. French pharma giant Sanofi (SNY - Free Report) markets Fabrazyme, which is approved for treating Fabry disease. Japan-based Takeda Pharmaceuticals’ Replagal, is also indicated for long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry Disease.
Sanofi also markets its Pompe disease drugs, Myozyme/Lumizyme, as well as Nexviazyme. Stiff competition from established players like Sanofi in the Pompe disease market remains a headwind.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Can Galafold Drive Amicus' Growth Through the Rest of 2025?
Key Takeaways
Amicus Therapeutics’ (FOLD - Free Report) lead product, Galafold (migalastat), has been driving the majority of the company’s revenues. The drug remains a key top-line driver for the company.
Galafold is the first oral precision medicine approved for treating patients with Fabry disease who have amenable genetic variants. The drug is approved in several countries across the world, including the United States, the European Union, the United Kingdom and Japan.
Amicus’ first marketed product, Galafold, has shown solid uptake since its launch. The sales of the drug have been rising consistently year over year. In the first six months of 2025, Galafold generated sales worth $233.1 million, which increased around 11% on a year-over-year basis. Our model estimates for Galafold sales suggest a CAGR of 11.7% over the next three years.
Label expansion, combined with approvals in additional geographies, has been driving Galafold sales in recent quarters, and the momentum is expected to continue in the remainder of 2025. The drug also has a strong IP portfolio in the United States, providing patent protection through 2038.
Last October, Amicus signed a licensing agreement with Teva Pharmaceuticals (TEVA - Free Report) , resolving the patent lawsuit that it had filed earlier. The litigation arose after Teva submitted an abbreviated new drug application seeking approval to sell a generic version of Amicus' Galafold 123 mg capsules before the related patents expired.
Per the settlement terms, TEVA will not be able to sell its generic version of Galafold in the United States until January 2037.
Besides Galafold, Amicus is also making good progress with Pombiliti (cipaglucosidase alfa) + Opfolda (miglustat), a two-component therapy, which is approved for treating adults with late-onset Pompe disease (LOPD). The approval of Pombiliti + Opfolda helped FOLD tap into a market with a significant commercial opportunity.
During the first six months of 2025, the combo drug generated sales worth $46.8 million, up around 74% on a year-over-year basis.
FOLD’s Dependence on Galafold & Competition in the Target Market
Currently, Amicus remains heavily dependent on Galafold for its overall revenue growth, making the company vulnerable to any regulatory setbacks for the drug. Though Pombiliti + Opfolda has been approved in Europe and the United States, it is yet to generate incremental sales. Any regulatory setback for the approved drugs will hinder the company’s growth prospects.
Also, competition looms large from established players in the target market. Several pharmaceutical and biotechnology companies currently market and sell products for treating lysosomal storage disorders, including Fabry disease. French pharma giant Sanofi (SNY - Free Report) markets Fabrazyme, which is approved for treating Fabry disease. Japan-based Takeda Pharmaceuticals’ Replagal, is also indicated for long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry Disease.
Sanofi also markets its Pompe disease drugs, Myozyme/Lumizyme, as well as Nexviazyme. Stiff competition from established players like Sanofi in the Pompe disease market remains a headwind.